Clinical Trials Directory

Trials / Completed

CompletedNCT00349128

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
382 (planned)
Sponsor
Solvay Pharmaceuticals · Industry
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Conditions

Interventions

TypeNameDescription
DRUGfenofibrate and metformin combination (drug)

Timeline

Start date
2004-01-01
First posted
2006-07-06
Last updated
2007-09-03

Locations

51 sites across 3 countries: Poland, Ukraine, United Kingdom

Source: ClinicalTrials.gov record NCT00349128. Inclusion in this directory is not an endorsement.

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes (NCT00349128) · Clinical Trials Directory